secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001213900-25-030129
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio presents MINDFul Phase 2 baseline data; top-line results expected June 2025
--------------------------------------------------------------------------------

- Poster at AD/PD conference details demographics: mean age 72.5 years, 69.2% APOE ε4 carriers.
- 64.9% of enrolled patients positive for >1 biomarker of immune dysfunction (hsCRP, ESR, HbA1C, APOE ε4).
- Trial enrolled patients with MCI or mild AD; EMACC composite used as primary cognitive endpoint.
- Screen failures driven mainly by MMSE inclusion criteria; enrollment completed November 2024.
- Top-line results from the 24-week, randomized, placebo-controlled study expected in June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025030129/0001213900-25-030129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025030129/ea0237701-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-030129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer